文献速递儿童感染儿童呼吸

13价肺炎球菌结合疫苗接种实施与儿童社区获得性肺炎发病率的长期关联

Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.
PubMed 文献 · JAMA Pediatr · 2019-01-01

结果显示,2010年PCV13实施后CAP频率显著下降(每月-0.8%),至2014年5月降至3.5例/1000儿科急诊就诊,此后略有回升(每月0.9%)至2017年5月的3.8例/1000。伴有胸腔积液的CAP、需住院的CAP和高炎症生物标志物CAP在PCV13实施后立即显著下降且无反弹。

要点

  • PCV13实施后CAP频率从6.3降至3.5例/1000儿科急诊就诊,降幅为每月-0.8%。
  • 伴有胸腔积液的CAP立即下降48%,需住院的CAP下降30%,高炎症标志物CAP下降30%,无反弹。
  • 2014年6月后CAP频率略有回升(每月0.9%),至2017年5月为3.8例/1000。

核心结论

  • PCV13实施7年后其相关变化仍然显著,尤其是伴有胸腔积液的CAP、需住院的CAP和高炎症生物标志物CAP。
  • 新出现的非PCV13血清型可能较少参与重症CAP,而与侵袭性肺炎球菌病的关系不同。

研究设计与样本

  • 准实验、基于人群的中断时间序列分析,基于2009年6月至2017年5月在法国8个儿科急诊科开展的前瞻性多中心研究。
  • 纳入所有15岁及以下、胸片确诊的CAP患者。
  • 采用分段回归模型分析每1000次儿科急诊就诊中CAP病例数随时间的变化,并针对流感样疾病综合征进行调整。

主要发现

  • 2010年PCV13实施后CAP频率急剧下降(每月-0.8% [95% CI, -1.0%至-0.5%]),从6.3例/1000儿科急诊就诊降至2014年5月的3.5例/1000。
  • 2014年6月后CAP频率略有上升(每月0.9% [95% CI, 0.4%-1.4%]),至2017年5月达3.8例/1000儿科急诊就诊。
  • 伴有胸腔积液的CAP立即下降48%(95% CI, -84%至-12%),需住院的CAP下降30%(95% CI, -56%至-5%),高炎症生物标志物CAP下降30%(95% CI, -54%至-6%),此后无反弹。

临床怎么用

  • PCV13接种实施与儿童CAP频率下降相关,尤其对伴有胸腔积液、需住院和高炎症生物标志物的重症CAP有显著持续影响。
  • 临床中应关注PCV13长期实施后CAP频率的轻微回升趋势,但重症CAP未见反弹。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In several countries, 5 years after 13-valent pneumococcal conjugate vaccine (PCV13) implementation, serotype replacement has been reported for invasive pneumococcal disease, which raises concerns about the long-term outcome of PCV13 implementation. The long-term effect of vaccination on community-acquired pneumonia (CAP) remains unknown. OBJECTIVE: To assess the long-term outcome of PCV13 implementation on CAP in children. DESIGN, SETTING, AND PARTICIPANTS: This quasi-experimental, population-based, interrupted time-series analysis was based on a prospective multicenter study conducted from June 2009 to May 2017 in 8 French pediatric emergency departments. All patients 15 years and younger with chest radiography-confirmed CAP were included. EXPOSURES: Community-acquired pneumonia. MAIN OUTCOMES AND MEASURES: The number of CAP cases per 1000 pediatric emergency department visits over time, analyzed using a segmented regression model, adjusted for influenza-like illness syndromes. RESULTS: We enrolled 12 587 children with CAP, including 673 cases of CAP with pleural effusion (5.3%), 4273 cases of CAP requiring hospitalization (33.9%), 2379 cases of CAP with high inflammatory biomarkers (18.9%), and 221 cases of proven pneumococcal CAP (1.8%). The implementation of PCV13 in 2010 was followed by a sharp decrease in the frequency of CAP (-0.8% per month [95% CI, -1.0% to -0.5% per month]), from 6.3 to 3.5 cases of CAP per 1000 pediatric emergency department visits until May 2014, then a slight increase since June 2014 (0.9% per month [95% CI, 0.4%-1.4% per month]), until 3.8 cases of CAP per 1000 pediatric emergency department visits in May 2017. There were marked immediate decreases in cases of CAP with pleural effusion (-48% [95% CI, -84% to -12%]), CAP requiring hospitalization (-30% [95% CI, -56% to -5%]), and CAP with high inflammatory biomarkers (-30% [95% CI, -54% to -6%]), without any rebound thereafter. CONCLUSIONS AND RELEVANCE: The changes associated with PCV13 use 7 years after implementation remain substantial, especially for CAP with pleural effusion, CAP requiring hospitalization, and CAP with high inflammatory biomarkers. Emerging non-PCV13 serotypes may be less likely involved in severe CAP than invasive pneumococcal disease.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Ouldali N, Levy C, Minodier P, et al. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children. JAMA Pediatr. 2019. PMID: 30715140. doi:10.1001/jamapediatrics.2018.5273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。